SAB Biotherapeutics, Inc. (SABS) Stock Grade

About SAB Biotherapeutics, Inc.'s fundamentals

SAB Biotherapeutics is a small-cap biotechnology company with a market capitalization of $72.2 million that is currently unprofitable, with a net margin of 0.0% and no dividend payments to shareholders. The company experienced a complete collapse in year-over-year revenue, declining 100.0%, indicating it generated no product sales during the most recent period. Despite the revenue decline, the company shows a relatively low P/E ratio of 5.4, though this metric is of limited utility given the lack of profitability. The 8.8% return on equity suggests modest returns on shareholder capital, though this figure must be interpreted cautiously given the company's current financial trajectory.